OraSure Technologies, Inc. (NASDAQ:OSUR) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Thursday.

A number of other brokerages have also commented on OSUR. Stephens reiterated an “overweight” rating and set a $19.00 price target (up from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. BidaskClub lowered OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Canaccord Genuity reiterated a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Saturday, September 9th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $23.00 price target on shares of OraSure Technologies in a report on Friday, October 20th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $18.21.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. OraSure Technologies had a return on equity of 14.82% and a net margin of 20.48%. The company had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. During the same period in the previous year, the company earned $0.11 earnings per share. The company’s quarterly revenue was up 31.0% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “ValuEngine Downgrades OraSure Technologies, Inc. (OSUR) to Hold” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/02/valuengine-downgrades-orasure-technologies-inc-osur-to-hold.html.

In other news, SVP Jack E. Jerrett sold 73,463 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $20.77, for a total transaction of $1,525,826.51. Following the sale, the senior vice president now directly owns 81,593 shares in the company, valued at $1,694,686.61. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Ronald H. Spair sold 510,112 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $20.66, for a total value of $10,538,913.92. Following the sale, the chief financial officer now owns 208,606 shares in the company, valued at $4,309,799.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 717,601 shares of company stock worth $14,977,398. 6.40% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in OSUR. UBS Asset Management Americas Inc. increased its position in shares of OraSure Technologies by 43.5% during the first quarter. UBS Asset Management Americas Inc. now owns 30,996 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 9,400 shares during the period. Parametric Portfolio Associates LLC increased its position in shares of OraSure Technologies by 103.1% during the first quarter. Parametric Portfolio Associates LLC now owns 178,035 shares of the medical instruments supplier’s stock valued at $2,302,000 after purchasing an additional 90,361 shares during the period. Victory Capital Management Inc. bought a new stake in shares of OraSure Technologies during the first quarter valued at approximately $100,000. American International Group Inc. increased its position in shares of OraSure Technologies by 7.1% during the first quarter. American International Group Inc. now owns 33,373 shares of the medical instruments supplier’s stock valued at $432,000 after purchasing an additional 2,203 shares during the period. Finally, OppenheimerFunds Inc. bought a new stake in shares of OraSure Technologies during the first quarter valued at approximately $824,000. Institutional investors and hedge funds own 92.88% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.